Related Experiment Video
Updated: Jan 6, 2026
Microvascular Decompression: Salient Surgical Principles and Technical Nuances
Published on: July 5, 2011
Clinical Research on Delayed Cure after Microvascular Decompression for Hemifacial Spasm
Ming-Wu Li1, Xiao-Feng Jiang1, Min Wu2,3
1Department of Neurosurgery, The First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Hospital, Anhui Provincial Stereotactic Neurological Institute, Anhui Provincial Key Laboratory of Brain Function and Disease, Hefei, Anhui, China.
Insights
Delayed cure after microvascular decompression (MVD) for hemifacial spasm (HFS) is linked to disease duration and severity. Consider this delay when assessing treatment outcomes and planning reoperations.
Area of Science:
- Neurosurgery
- Neurology
- Clinical Medicine
Background:
- Hemifacial spasm (HFS) is a neurological disorder characterized by involuntary muscle contractions on one side of the face.
- Microvascular decompression (MVD) is a primary surgical treatment for HFS, aiming to alleviate neurovascular compression.
- Understanding factors influencing treatment outcomes is crucial for optimizing patient care.
Purpose of the Study:
- To statistically analyze clinical data of patients with HFS undergoing MVD.
- To identify specific factors associated with delayed cure following MVD surgery.
- To provide insights for managing patient expectations and treatment strategies.
Main Methods:
- Retrospective analysis of clinical data from 600 HFS patients who underwent MVD.
- Statistical methods included Student t test, chi-square test, logistic regression, and multivariate analysis of variance.
- Correlation between delayed cure and factors like disease course, HFS severity, and intraoperative findings were assessed.
Main Results:
- 117 out of 600 patients experienced delayed cure, averaging 108 days (range: 4-540 days).
- Delayed cure was not associated with sex, age, or offending vessel type (p > 0.05).
- Positive correlations were found between delayed cure and longer disease duration, higher HFS severity grade, and intraoperative disappearance of abnormal muscle responses (p < 0.05).
Conclusions:
- MVD is an effective treatment for HFS, but delayed cure can occur.
- Factors such as disease duration and severity influence the time to recovery.
- Delayed cure should be anticipated in reoperation cases, and efficacy assessments should be timed accordingly.
Objective:
The clinical data of patients with hemifacial spasm (HFS) were analyzed statistically to identify factors leading to delayed cure after microvascular decompression (MVD).
Methods:
A retrospective analysis of the clinical data of 600 patients with HFS subjected to MVD from March 2016 to May 2018 was performed. Student t test, chi-square test, logistic regression analysis, and multivariate analysis of variance were used to analyze the correlation between delayed cure and its related factors.
Results:
Among the 600 patients enrolled, 117 had delayed cure after MVD. The shortest duration of delayed cure was 4 days, and the longest was 540 days, with an average of 108 days. The frequency of delayed improvement in these patients was not associated with sex, age, or offending vessel type (p > 0.05); however, delayed cure was positively correlated with the course of the disease, grade of HFS severity, and disappearance of abnormal muscle responses during the operation (p < 0.05). Moreover, a longer disease course was associated with more severe related symptoms and a longer duration of postoperative delayed cure.
Conclusion:
MVD is an effective treatment for HFS. Given that postoperative delayed cure was unavoidable, even with accurate identification of the offending vessel and sufficient decompression of the root exit zone, delayed cure should be considered in patients undergoing reoperation due to lack of remission or relapse after the operation. Additionally, the timing of efficacy assessments should be delayed.
